Francesco Alesiani
- Co-authors
- Massimo OffidaniMassimo CatariniPietro LeoniGiuseppe VisaniAttilio OlivieriLaura CorvattaMarino BrunoriRiccardo Centurioni
- Topics
- Multiple Myeloma Research and Treatments (14 papers)Protein Degradation and Inhibitors (9 papers)Peptidase Inhibition and Analysis (8 papers)
- Partner nations
- ItalyUnited KingdomPoland
In The Last Decade
Francesco Alesiani
24 papers receiving 424 citations
Peers
Comparison fields: 5 of 64
- Hematology 223
- Molecular Biology 205
- Oncology 180
- Pathology and Forensic Medicine 64
- Pharmacology 63
Countries citing papers authored by Francesco Alesiani
This map shows the geographic impact of Francesco Alesiani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Francesco Alesiani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Francesco Alesiani more than expected).
Fields of papers citing papers by Francesco Alesiani
This network shows the impact of papers produced by Francesco Alesiani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Francesco Alesiani. The network helps show where Francesco Alesiani may publish in the future.
Co-authorship network of co-authors of Francesco Alesiani
This figure shows the co-authorship network connecting the top 25 collaborators of Francesco Alesiani. A scholar is included among the top collaborators of Francesco Alesiani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Francesco Alesiani. Francesco Alesiani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 4 | |
| 2 | 6 | |
| 3 | 90 | |
| 4 | 41 | |
| 5 | 36 | |
| 6 | 47 | |
| 7 | 17 | |
| 8 | 5 | |
| 9 | 1 | |
| 10 | 1 | |
| 11 | 12 | |
| 12 | 4 | |
| 13 | 23 | |
| 14 | 34 | |
| 15 | 9 | |
| 16 | Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma: a prospective, multicenter, phase II study. | 62 |
| 17 | 2 | |
| 18 | 1 | |
| 19 | 10 | |
| 20 | Two dosage interferon-alpha 2b maintenance therapy in patients affected by low-risk multiple myeloma in plateau phase: a randomized trial. | 4 |
About Francesco Alesiani
Francesco Alesiani is a scholar working on Hematology, Oncology and Molecular Biology, having authored 25 papers that have together received 432 indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (14 papers), Protein Degradation and Inhibitors (9 papers) and Peptidase Inhibition and Analysis (8 papers). The work is most often cited by research in Hematology (223 citations), Geriatrics and Gerontology (26 citations) and Oncology (180 citations). Francesco Alesiani has collaborated with scholars based in Italy, United Kingdom and Poland. Frequent co-authors include Massimo Offidani, Massimo Catarini, Pietro Leoni, Giuseppe Visani, Attilio Olivieri, Laura Corvatta, Marino Brunori, Riccardo Centurioni, Giorgio Santoni and Silvia Gentili. Their work appears in journals such as Blood, PLoS ONE and International Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.